Market Overview

UPDATE: Piper Jaffray Initiates Inovio Pharmaceuticals at Overweight on DNA Vaccine Outlook

Share:
Related INO
12 Biggest Mid-Day Gainers For Wednesday
Positive Zika Vaccine Update May Ignite Inovio Short Squeeze

Piper Jaffray initiated coverage on Inovio Pharmaceuticals (NYSE: INO) with an Overweight rating and a $1.00 price target.

Piper Jaffray noted, "Inovio is developing a novel DNA-based vaccine platform, utilizing proprietary electroporation technology to create robust immune responses. Inovio's vaccines have demonstrated provocative immune responses in early studies against a multiple non-viral oncology targets (prostate, leukemia, breast, lung), as well as several infectious diseases HIV, HCV, HPV, and the flu. Based on earlier validation for producing uncommonly robust T-Cell responses, we are optimistic for the data expected in 4Q13, but note multiple Phase II catalysts expected this year in HCV and leukemia."

Inovio Pharmaceuticals closed at $0.67 on Thursday.

Latest Ratings for INO

DateFirmActionFromTo
Nov 2016Aegis CapitalInitiates Coverage OnBuy
Oct 2016Brean CapitalAssumesBuy
Aug 2016Maxim GroupDowngradesBuyHold

View More Analyst Ratings for INO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (INO)

View Comments and Join the Discussion!